ReviewUrolithiasis2019
Molecular basis of primary hyperoxaluria: clues to innovative treatments.
Review in Urolithiasis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 73 citations in OpenAlex.
- siRNA Therapeutics for the Treatment of Hereditary Diseases and Other Conditions: A Review.International journal of molecular sciences · 2025Review
- Mendelian randomization study of micronutrients and development of CKD in a Korean population.Nutrition journal · 2025Article
- Engineered Oxalate Decarboxylase Boosts Activity and Stability for Biological Applications.ACS omega · 2025Article
- Effect of the allelic background on the phenotype of primary hyperoxaluria type I.Current opinion in nephrology and hypertension · 2025Review
- Opportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory.Kidney international reports · 2024Article
- Comparative transcriptome and methylome of polar bears, giant and red pandas reveal diet-driven adaptive evolution.Evolutionary applications · 2024Article
- LDLR-Mediated Targeting and Productive Uptake of siRNA-Peptide Ligand Conjugates In Vitro and In Vivo.Pharmaceutics · 2024Article
- Harnessing inter-kingdom metabolic disparities at the human-fungal interface for novel therapeutic approaches.Frontiers in molecular biosciences · 2024Article
- Natural history of urine and plasma oxalate in children with primary hyperoxaluria type 1.Pediatric nephrology (Berlin, Germany) · 2024Observational
- Multiplex gene editing reduces oxalate production in primary hyperoxaluria type 1.Zoological research · 2023Article
- Clinical and molecular characterization of a large primary hyperoxaluria cohort from Saudi Arabia: a retrospective study.Pediatric nephrology (Berlin, Germany) · 2023Article
- Serum metabolomics strategy for investigating the hepatotoxicity induced by different exposure times and doses ofRSC advances · 2023Article
- Clinical and molecular characterization of primary hyperoxaluria in Egypt.Scientific reports · 2022Article
- Design and Synthesis of New Pyrimidine-Quinolone Hybrids as NovelPharmaceuticals (Basel, Switzerland) · 2022Article
- Efficient and Fast Generation of Relevant Disease Mouse Models byThe CRISPR journal · 2022Article
- Primary hyperoxaluria type 1 in developing countries: novel challenges in a new therapeutic era.Clinical kidney journal · 2022Review
- Primary hyperoxaluria type 1: novel therapies at a glance.Clinical kidney journal · 2022Review
- Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2022Article
- Article
- Perspectives in primary hyperoxaluria - historical, current and future clinical interventions.Nature reviews. Urology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Primary hyperoxalurias (PHs) are rare inherited disorders of liver glyoxylate metabolism, characterized by the abnormal production of endogenous oxalate, a metabolic end-product that is eliminated by urine. The main symptoms are related to the precipitation of calcium oxalate crystals in the urinary tract with progressive renal damage and, in the most severe form named Primary Hyperoxaluria Type I (PH1), to systemic oxalosis. The therapies currently available for PH are either poorly effective, because they address the symptoms and not the causes of the disease, or highly invasive. In the last years, advances in our understanding of the molecular bases of PH have paved the way for the development of new therapeutic strategies. They include (i) substrate-reduction therapies based on small-molecule inhibitors or the RNA interference technology, (ii) gene therapy, (iii) enzyme administration approaches, (iv) colonization with oxalate-degrading intestinal microorganisms, and, in PH1, (v) design of pharmacological chaperones. This paper reviews the basic principles of these new therapeutic strategies and what is currently known about their application to PH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.